Skip to main content
Erschienen in: Pathology & Oncology Research 3/2008

01.09.2008 | Original Paper

Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature

verfasst von: D. A. Morgenstern, H. Rees, N. J. Sebire, J. Shipley, John Anderson

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Myogenin immunostaining has been described as a useful marker of the alveolar subtype of rhabdomyosarcoma and as a tool for distinguishing it from the more common embryonal subtype. To add to the growing body of literature describing this phenomenon we analysed myogenin immunohistochemical staining in 152 tumors using a rhabdomyosarcoma tissue array. Results were analysed blinded to histological type by two independent investigators. Samples were excluded if any samples failed to stain with desmin and/or myogenin. Mean percentage of myogenin positive cells was significantly greater for ARMS (n = 31; mean percentage positivity 59% (95% confidence intervals ± 7%) than ERMS (n = 41, mean percentage positivity 16%, 95% confidence intervals ± 4; P < 0.0001). This data is consistent with previously published studies identifying strong nuclear myogenin staining in a high proportion of cells as a marker of alveolar histology.
Literatur
1.
Zurück zum Zitat McManus AP, O'Reilly MA, Jones KP, Gusterson BA, Mitchell CD, Pinkerton CR, Shipley JM (1996) Interphase fluorescence in situ hybridization detection of t(2;13)(q35;q14) in alveolar rhabdomyosarcoma–a diagnostic tool in minimally invasive biopsies. J Pathol 178:410–414CrossRefPubMed McManus AP, O'Reilly MA, Jones KP, Gusterson BA, Mitchell CD, Pinkerton CR, Shipley JM (1996) Interphase fluorescence in situ hybridization detection of t(2;13)(q35;q14) in alveolar rhabdomyosarcoma–a diagnostic tool in minimally invasive biopsies. J Pathol 178:410–414CrossRefPubMed
2.
Zurück zum Zitat Sapi Z, Antal I, Papai Z, Szendroi M, Mayer A, Jakab K, Pajor L, Bodo M (2002) Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques. Diagn Cytopathol 26:232–242CrossRefPubMed Sapi Z, Antal I, Papai Z, Szendroi M, Mayer A, Jakab K, Pajor L, Bodo M (2002) Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques. Diagn Cytopathol 26:232–242CrossRefPubMed
3.
Zurück zum Zitat Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K (2001) Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 85:831–835CrossRefPubMed Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K (2001) Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 85:831–835CrossRefPubMed
4.
Zurück zum Zitat Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20:2672–2679CrossRefPubMed Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20:2672–2679CrossRefPubMed
5.
Zurück zum Zitat Sebire NJ, Malone M (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56:412–416CrossRefPubMed Sebire NJ, Malone M (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56:412–416CrossRefPubMed
6.
Zurück zum Zitat Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24:816–822CrossRefPubMed Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24:816–822CrossRefPubMed
7.
Zurück zum Zitat Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, Coffin CM (2001) Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25:1150–1157CrossRefPubMed Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, Coffin CM (2001) Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25:1150–1157CrossRefPubMed
8.
Zurück zum Zitat Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM (1995) Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 147:1799–1810PubMed Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM (1995) Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 147:1799–1810PubMed
9.
Zurück zum Zitat Folpe AL (2002) MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Pathol 9:198–203CrossRefPubMed Folpe AL (2002) MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Pathol 9:198–203CrossRefPubMed
10.
Zurück zum Zitat Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M (2000) Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 13:988–993CrossRefPubMed Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M (2000) Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 13:988–993CrossRefPubMed
11.
Zurück zum Zitat Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, Lussan C, Longavenne E, Bui NB, Delattre O, Coindre JM (2004) Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101:2817–2824CrossRefPubMed Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, Lussan C, Longavenne E, Bui NB, Delattre O, Coindre JM (2004) Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101:2817–2824CrossRefPubMed
12.
Zurück zum Zitat Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, Parham D, Qualman S, Houghton P (2000) Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156:399–408PubMed Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, Parham D, Qualman S, Houghton P (2000) Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156:399–408PubMed
13.
Zurück zum Zitat Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ (2006) An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 30:962–968CrossRefPubMed Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ (2006) An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 30:962–968CrossRefPubMed
14.
Zurück zum Zitat Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed
Metadaten
Titel
Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature
verfasst von
D. A. Morgenstern
H. Rees
N. J. Sebire
J. Shipley
John Anderson
Publikationsdatum
01.09.2008
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2008
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9012-5

Weitere Artikel der Ausgabe 3/2008

Pathology & Oncology Research 3/2008 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.